Literature DB >> 13680438

Effects of past noninjection drug abuse upon executive function and working memory in HIV infection.

Michael R Basso1, Robert A Bornstein.   

Abstract

Interactive effects of past noninjection drug abuse/dependence and HIV disease status upon measures of executive function were assessed in a group of 294 homosexual men. Participants were stratified according to HIV status and substance use diagnoses, thereby yielding a 4 (seronegative, asymptomatic seropositive, symptomatic seropositive, and AIDS defining illness) x 2 (never abused drugs, previous substance use disorder) design. Significant main effects of HIV status were found on the Wisconsin Card Sorting Test, Ruff Figural Fluency Test, Trail Making Test B, and total number of impaired performances. Analyses revealed that men with AIDS defining illness performed worse than the other three groups. Drug use history had no significant effect upon neurobehavioral function, and effect sizes for drug abuse history were small. The data suggest that prior drug use yields little if any residual cognitive impairment in HIV infection.

Entities:  

Mesh:

Year:  2003        PMID: 13680438     DOI: 10.1076/jcen.25.7.893.16489

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  13 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Modeling deficits in attention, inhibition, and flexibility in HAND.

Authors:  Landhing M Moran; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-25       Impact factor: 4.147

3.  Neuropsychological Dysfunction among HIV Infected Drug Abusers.

Authors:  Ramani S Durvasula; Charles H Hinkin
Journal:  Am J Infect Dis       Date:  2006

4.  Procedural learning impairments identified via predictive saccades in chronic traumatic brain injury.

Authors:  Marilyn F Kraus; Deborah M Little; Sydney M Wojtowicz; John A Sweeney
Journal:  Cogn Behav Neurol       Date:  2010-12       Impact factor: 1.600

Review 5.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

Review 6.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

7.  Isolating cognitive and neurologic HIV effects in substance-dependent, confounded cohorts: a pilot study.

Authors:  Desiree A Byrd; Jessica Robinson-Papp; Monica Rivera Mindt; Letty Mintz; Kathryn Elliott; Quenesha Lighty; Susan Morgello
Journal:  J Int Neuropsychol Soc       Date:  2013-02-28       Impact factor: 2.892

8.  Cognitive mechanisms of switching in HIV-associated category fluency deficits.

Authors:  Jennifer E Iudicello; Steven Paul Woods; Erica Weber; Matthew S Dawson; J Cobb Scott; Catherine L Carey; Igor Grant
Journal:  J Clin Exp Neuropsychol       Date:  2008-03-04       Impact factor: 2.475

9.  The longitudinal and interactive effects of HIV status, stimulant use, and host genotype upon neurocognitive functioning.

Authors:  Andrew J Levine; Sandra Reynolds; Christopher Cox; Eric N Miller; Janet S Sinsheimer; James T Becker; Eileen Martin; Ned Sacktor
Journal:  J Neurovirol       Date:  2014-04-16       Impact factor: 2.643

Review 10.  Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features.

Authors:  Eileen M Martin-Thormeyer; Robert H Paul
Journal:  Neuropsychol Rev       Date:  2009-05-27       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.